| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men |
| Source | U.S. News & World Report (HealthDay) |
| URL | usnews.com/news/health-news/articles/2026-06-23/testosterone-therapy-labels-and-limits-may-change-under-fda-proposal (opens in a new tab) |
Specific Claim Evaluated
The FDA has asked manufacturers to update testosterone prescribing information by removing the limitation of use in age-related hypogonadism, restricting the prostate cancer contraindication to metastatic disease and revising the benign prostatic hyperplasia warning.
Primary Research Supporting or Contradicting the Claim
The FDA confirmed that it requested updates to testosterone prescribing information in June 2026 (U.S. Food and Drug Administration, 2026b). The cardiovascular rationale draws on TRAVERSE, in which daily transdermal testosterone was noninferior to placebo for major adverse cardiac events in 5,246 men aged 45 to 80 years with confirmed hypogonadism and preexisting or high cardiovascular risk, with a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group (Lincoff et al., 2023).
Corrected Evidence-Based Interpretation
The report is correct. The changes are requested labeling revisions; revised labels take effect only after sponsor submission and FDA review. TRAVERSE data apply to men with symptoms and 2 fasting testosterone values below 300 ng/dL, not to men with normal testosterone.
Rationale for Grade
The article frames the action as a proposal, attributes it to the HHS and FDA release, and reports each of the 3 requested changes without presenting them as final. It does not describe the TRAVERSE safety signals, but the item is a short regulatory news report and the omission does not alter the meaning of what is reported. No claim in the article conflicts with the regulatory record or the trial data.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"